Q3 EPS Forecast for Inovio Pharmaceuticals Lifted by Analyst

Key Points

• HC Wainwright revised their earnings per share (EPS) forecast for Inovio Pharmaceuticals' Q3 2025 from ($0.57) to ($0.54), while maintaining a "Neutral" rating and a $3.00 price objective.
• Inovio Pharmaceuticals recently posted quarterly earnings of (0.61) EPS, outperforming the consensus estimate of (0.63) EPS by $0.02.
• The stock has seen significant interest from institutional investors, with multiple new positions established in recent quarters, reflecting a growing belief in its long-term potential.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) - Equities research analysts at HC Wainwright boosted their Q3 2025 earnings per share estimates for Inovio Pharmaceuticals in a research report issued on Thursday, August 14th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings of ($0.54) per share for the quarter, up from their prior forecast of ($0.57). HC Wainwright currently has a "Neutral" rating and a $3.00 price target on the stock. The consensus estimate for Inovio Pharmaceuticals' current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals' Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($2.09) EPS, Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at $0.28 EPS and FY2026 earnings at ($1.33) EPS.

Several other equities research analysts have also recently commented on the company. Royal Bank Of Canada reaffirmed a "sector perform" rating and set a $5.00 target price on shares of Inovio Pharmaceuticals in a research note on Wednesday, May 14th. Piper Sandler assumed coverage on Inovio Pharmaceuticals in a research note on Wednesday, July 9th. They set an "overweight" rating and a $5.00 price target on the stock. Wall Street Zen cut shares of Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. Finally, Oppenheimer cut their price objective on shares of Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating on the stock in a report on Wednesday, May 14th. Three research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Inovio Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $8.80.

Inovio Pharmaceuticals Trading Up 2.4%

INO stock traded up $0.0450 during midday trading on Monday, hitting $1.8950. The stock had a trading volume of 430,237 shares, compared to its average volume of 1,214,819. The business has a fifty day moving average price of $1.66 and a two-hundred day moving average price of $1.83. Inovio Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $7.76. The firm has a market cap of $69.50 million, a P/E ratio of -0.73 and a beta of 1.38.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.02.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC raised its holdings in shares of Inovio Pharmaceuticals by 221.2% during the 2nd quarter. Jane Street Group LLC now owns 39,683 shares of the biopharmaceutical company's stock valued at $81,000 after buying an additional 27,329 shares in the last quarter. Qube Research & Technologies Ltd purchased a new stake in Inovio Pharmaceuticals during the second quarter valued at about $234,000. Catalyst Funds Management Pty Ltd bought a new position in Inovio Pharmaceuticals during the 2nd quarter worth approximately $35,000. Bank of Montreal Can increased its stake in shares of Inovio Pharmaceuticals by 23.7% in the second quarter. Bank of Montreal Can now owns 57,946 shares of the biopharmaceutical company's stock worth $118,000 after buying an additional 11,110 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new stake in Inovio Pharmaceuticals during the 2nd quarter valued at $86,000. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.